Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTCNASDAQ:ERASNASDAQ:EXOZNASDAQ:MREO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTCBenitec Biopharma$15.39-6.6%$14.11$5.74▼$17.15$404.75M0.4441,809 shs27,777 shsERASErasca$1.39-6.4%$1.34$1.01▼$3.45$392.35M1.091.56 million shs557,500 shsEXOZExozymes$12.77-0.3%$12.68$8.50▼$23.99$106.86MN/A17,019 shs1,003 shsMREOMereo BioPharma Group$2.82+2.0%$2.36$1.58▼$5.02$449.18M0.471.10 million shs314,053 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTCBenitec Biopharma0.00%+3.00%+21.18%+7.43%+125.44%ERASErasca0.00%-7.50%+15.18%+1.37%-31.80%EXOZExozymes0.00%-4.69%-14.83%-9.79%+1,280,999,900.00%MREOMereo BioPharma Group0.00%+0.73%+23.21%+4.94%-35.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNTCBenitec Biopharma2.4876 of 5 stars3.62.00.00.03.02.50.0ERASErasca2.6896 of 5 stars3.50.00.00.03.62.51.3EXOZExozymesN/AN/AN/AN/AN/AN/AN/AN/AMREOMereo BioPharma Group1.8677 of 5 stars3.61.00.00.02.81.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTCBenitec Biopharma 3.22Buy$23.8354.90% UpsideERASErasca 3.00Buy$4.57230.07% UpsideEXOZExozymes 0.00N/AN/AN/AMREOMereo BioPharma Group 3.17Buy$7.67172.35% UpsideCurrent Analyst Ratings BreakdownLatest EXOZ, MREO, BNTC, and ERAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025BNTCBenitec BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.005/15/2025BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.005/14/2025ERASErascaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$3.005/13/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.004/30/2025ERASErascaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/10/2025BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$18.00 ➝ $20.004/9/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/27/2025MREOMereo BioPharma GroupJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$7.003/26/2025ERASErascaRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.003/26/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/24/2025BNTCBenitec BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTCBenitec Biopharma$80K5,048.53N/AN/A$3.24 per share4.75ERASErascaN/AN/AN/AN/A$2.10 per shareN/AEXOZExozymesN/AN/AN/AN/AN/AN/AMREOMereo BioPharma Group$1M447.59N/AN/A$0.36 per share7.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTCBenitec Biopharma-$21.75M-$1.51N/AN/AN/AN/A-44.61%-41.25%N/AERASErasca-$125.04M-$0.62N/AN/AN/AN/A-42.26%-34.97%8/11/2025 (Estimated)EXOZExozymesN/AN/A0.00∞N/AN/AN/AN/AN/AMREOMereo BioPharma Group-$29.47M-$0.07N/AN/AN/AN/AN/AN/A8/12/2025 (Estimated)Latest EXOZ, MREO, BNTC, and ERAS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q3 2025BNTCBenitec Biopharma-$0.36-$0.24+$0.12-$0.24N/AN/A5/13/2025Q1 2025ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A5/13/2025Q1 2025MREOMereo BioPharma Group-$0.01-$0.02-$0.01-$0.02$72.50 millionN/A5/12/2025Q1 2025EXOZExozymesN/A-$0.22N/A-$0.22N/AN/A3/26/2025Q4 2024MREOMereo BioPharma Group$0.02-$0.01-$0.03-$0.01$72.50 millionN/A3/20/2025Q4 2024ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNTCBenitec BiopharmaN/AN/AN/AN/AN/AERASErascaN/AN/AN/AN/AN/AEXOZExozymesN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTCBenitec BiopharmaN/A25.4815.01ERASErascaN/A11.0011.00EXOZExozymesN/AN/AN/AMREOMereo BioPharma GroupN/A6.106.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTCBenitec Biopharma52.19%ERASErasca67.78%EXOZExozymesN/AMREOMereo BioPharma Group62.83%Insider OwnershipCompanyInsider OwnershipBNTCBenitec Biopharma1.30%ERASErasca14.40%EXOZExozymesN/AMREOMereo BioPharma Group5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTCBenitec Biopharma2026.25 million23.15 millionNo DataERASErasca120283.29 million221.94 millionOptionableEXOZExozymes298.37 millionN/AN/AMREOMereo BioPharma Group40159.00 million148.74 millionOptionableEXOZ, MREO, BNTC, and ERAS HeadlinesRecent News About These CompaniesBrokers Offer Predictions for MREO FY2026 EarningsJune 13 at 3:01 AM | americanbankingnews.comResearch Analysts Issue Forecasts for MREO FY2026 EarningsJune 11, 2025 | marketbeat.comMereo rebrands as Cedar TraceJune 10, 2025 | royalgazette.comInvestors Buy Large Volume of Call Options on Mereo BioPharma Group (NASDAQ:MREO)June 7, 2025 | americanbankingnews.comInvestors Purchase Large Volume of Call Options on Mereo BioPharma Group (NASDAQ:MREO)June 6, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes Position in Mereo BioPharma Group plc (NASDAQ:MREO)June 5, 2025 | marketbeat.comMereo BioPharma Group plc (NASDAQ:MREO) Given Consensus Recommendation of "Buy" by AnalystsMay 31, 2025 | marketbeat.comWoodline Partners LP Buys Shares of 618,784 Mereo BioPharma Group plc (NASDAQ:MREO)May 27, 2025 | marketbeat.comTema Etfs LLC Invests $3.12 Million in Mereo BioPharma Group plc (NASDAQ:MREO)May 20, 2025 | marketbeat.comJanus Henderson Group PLC Boosts Stock Holdings in Mereo BioPharma Group plc (NASDAQ:MREO)May 16, 2025 | marketbeat.comMereo BioPharma Group (MREO) to Release Quarterly Earnings on WednesdayMay 16, 2025 | marketbeat.comWhy Mereo BioPharma Group plc’s (MREO) Stock Is Down 5.63%May 16, 2025 | aaii.comWe're Not Very Worried About Mereo BioPharma Group's (NASDAQ:MREO) Cash Burn RateMay 15, 2025 | finance.yahoo.comMereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate HighlightsMay 13, 2025 | finanznachrichten.deMereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate HighlightsMay 13, 2025 | globenewswire.comMereo acquires Dish FiberMay 2, 2025 | advanced-television.comMereo BioPharma Group plc (MREO): A Bull Case TheoryApril 18, 2025 | finance.yahoo.comIs Mereo BioPharma Group (NASDAQ:MREO) the Best Biotech Penny Stock to Buy According to Hedge Funds?April 16, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Avidity Biosciences (RNA), Mereo Biopharma Group Plc (MREO) and Doximity (DOCS)April 9, 2025 | markets.businessinsider.comMereo BioPharma’s SWOT analysis: rare disease stock poised for breakthroughApril 2, 2025 | uk.investing.comMereo BioPharma initiated with an Overweight at JPMorganMarch 27, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEXOZ, MREO, BNTC, and ERAS Company DescriptionsBenitec Biopharma NASDAQ:BNTC$15.39 -1.09 (-6.64%) As of 12:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Erasca NASDAQ:ERAS$1.38 -0.10 (-6.42%) As of 12:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Exozymes NASDAQ:EXOZ$12.77 -0.04 (-0.31%) As of 11:25 AM EasterneXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.Mereo BioPharma Group NASDAQ:MREO$2.82 +0.06 (+1.99%) As of 12:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 2 Reasons Adobe Stock Is Ready to Rally This Year AMD Accelerates Stack Development: Share Price to Follow Alphabet Enters a Bull Market: Is It Time to Buy? Micron Joins Latest $200 Billion United States Investment Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Tariff Talks Advance, What Taiwan Semiconductor Can Deliver Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
